Sellas Life Sciences Group Inc Net Assets
Sellas Life Sciences Group Inc net assets. Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has net assets worth $137.66 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($145.38 Million) and total liabilities ($7.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore SLS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $137.66 Million |
| % of Total Assets | 94.69% |
| Annual Growth Rate | 11.0% |
| 5-Year Change | 248.31% |
| 10-Year Change | 147.31% |
| Growth Volatility | 237.25 |
Net Assets of Sellas Life Sciences Group Inc (2007–2025)
Net assets of Sellas Life Sciences Group Inc from 2007 to 2025. This chart illustrates how Sellas Life Sciences Group Inc's net assets have evolved over time, based on quarterly financial data. See SLS equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Sellas Life Sciences Group Inc (2007–2025)
The table below shows the annual net assets of Sellas Life Sciences Group Inc from 2007 to 2025. For live market cap and overall valuation, see SLS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $70.87 Million | +648.77% |
| 2024-12-31 | $9.46 Million | +218.67% |
| 2023-12-31 | $-7.98 Million | -264.42% |
| 2022-12-31 | $4.85 Million | -76.16% |
| 2021-12-31 | $20.35 Million | -27.23% |
| 2020-12-31 | $27.96 Million | +358.90% |
| 2019-12-31 | $6.09 Million | +16.17% |
| 2018-12-31 | $5.25 Million | +153.38% |
| 2017-12-31 | $2.07 Million | -92.78% |
| 2016-12-31 | $28.66 Million | +112.07% |
| 2015-12-31 | $13.51 Million | -63.54% |
| 2014-12-31 | $37.06 Million | +529.61% |
| 2013-12-31 | $5.89 Million | -78.79% |
| 2012-12-31 | $27.76 Million | +174.49% |
| 2011-12-31 | $10.11 Million | +316.13% |
| 2010-12-31 | $2.43 Million | +227.94% |
| 2009-12-31 | $741.00K | -91.74% |
| 2008-12-31 | $8.97 Million | -17.14% |
| 2007-12-31 | $10.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sellas Life Sciences Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27498800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Sellas Life Sciences Group Inc Net Assets Breakdown (December 2025)
Sellas Life Sciences Group Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00K | 0.02% |
| Other Components | $345.84 Million | 487.99% |
| Total Equity | $70.87 Million | 100.00% |
Sellas Life Sciences Group Inc Competitors by Market Cap
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Westshore Terminals Investment Corp
TO:WTE
|
$1.95 Billion |
|
Cyfrowy Polsat SA
WAR:CPS
|
$1.96 Billion |
|
Centrus Energy Corp.
NYSE MKT:LEU
|
$1.96 Billion |
|
Henan Yuneng Holdings Co Ltd
SHE:001896
|
$1.96 Billion |
|
Evergreen Aviation Tech Corp
TW:2645
|
$1.95 Billion |
|
Minerals Technologies Inc
NYSE:MTX
|
$1.95 Billion |
|
Whirlpool Corporation
NYSE:WHR
|
$1.95 Billion |
|
Chang Wah Technology Co Ltd
TWO:6548
|
$1.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sellas Life Sciences Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,465,000 to 70,871,000, a change of 61,406,000 (648.8%).
- Net loss of 26,863,000 reduced equity.
- New share issuances of 23,051,000 increased equity.
- Other factors increased equity by 65,218,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.86 Million | -37.9% |
| Share Issuances | $23.05 Million | +32.53% |
| Other Changes | $65.22 Million | +92.02% |
| Total Change | $- | 648.77% |
Book Value vs Market Value Analysis
This analysis compares Sellas Life Sciences Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.30x to 14.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.53 | $9.68 | x |
| 2007-12-31 | $2849.66 | $9.68 | x |
| 2008-12-31 | $2175.64 | $9.68 | x |
| 2009-12-31 | $152.47 | $9.68 | x |
| 2010-12-31 | $441.18 | $9.68 | x |
| 2011-12-31 | $927.79 | $9.68 | x |
| 2012-12-31 | $1481.27 | $9.68 | x |
| 2013-12-31 | $217.56 | $9.68 | x |
| 2014-12-31 | $1034.85 | $9.68 | x |
| 2015-12-31 | $675.65 | $9.68 | x |
| 2016-12-31 | $86.33 | $9.68 | x |
| 2017-12-31 | $44.22 | $9.68 | x |
| 2018-12-31 | $20.05 | $9.68 | x |
| 2019-12-31 | $2.38 | $9.68 | x |
| 2020-12-31 | $3.51 | $9.68 | x |
| 2021-12-31 | $1.31 | $9.68 | x |
| 2022-12-31 | $0.25 | $9.68 | x |
| 2023-12-31 | $-0.29 | $9.68 | x |
| 2024-12-31 | $0.15 | $9.68 | x |
| 2025-12-31 | $0.65 | $9.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sellas Life Sciences Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-37.90%) is above the historical average (-6452.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -120250.00% | 0.00% | 0.00x | 1.00x | $-2.41 Million |
| 2007 | -101.54% | 0.00% | 0.00x | 1.12x | $-12.07 Million |
| 2008 | -160.27% | 0.00% | 0.00x | 1.16x | $-15.27 Million |
| 2009 | -2481.38% | 0.00% | 0.00x | 8.44x | $-18.46 Million |
| 2010 | -493.54% | 0.00% | 0.00x | 3.08x | $-12.24 Million |
| 2011 | -113.58% | 0.00% | 0.00x | 3.06x | $-12.50 Million |
| 2012 | -125.99% | -1715.85% | 0.04x | 1.98x | $-37.74 Million |
| 2013 | -1302.72% | -3083.15% | 0.03x | 14.95x | $-77.27 Million |
| 2014 | -98.78% | -392.81% | 0.12x | 2.17x | $-40.31 Million |
| 2015 | -472.89% | 0.00% | 0.00x | 6.08x | $-65.25 Million |
| 2016 | -82.18% | 0.00% | 0.00x | 2.30x | $-26.41 Million |
| 2017 | -1147.54% | 0.00% | 0.00x | 16.20x | $-23.96 Million |
| 2018 | -527.55% | 0.00% | 0.00x | 3.22x | $-28.19 Million |
| 2019 | -316.63% | 0.00% | 0.00x | 2.73x | $-19.90 Million |
| 2020 | -59.93% | -881947.37% | 0.00x | 1.65x | $-19.55 Million |
| 2021 | -101.73% | -272.36% | 0.29x | 1.30x | $-22.73 Million |
| 2022 | -851.39% | -4130.10% | 0.05x | 4.32x | $-41.79 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.54 Million |
| 2024 | -326.27% | 0.00% | 0.00x | 2.05x | $-31.83 Million |
| 2025 | -37.90% | 0.00% | 0.00x | 1.11x | $-33.95 Million |
Industry Comparison
This section compares Sellas Life Sciences Group Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sellas Life Sciences Group Inc (SLS) | $137.66 Million | -120250.00% | 0.06x | $1.95 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more